Нитрозивный и оксидативный стресс при заболеваниях органов дыхания

Заболевания органов дыхания сопровождаются интенсификацией свободнорадикальных процессов на разных уровнях биологической организации организма с одновременным напряжением и последующим угнетением различных звеньев антиоксидантной защиты, что приводит к развитию оксидативного (ОС) и нитрозивного (НС) стресса. Рассмотрены основные механизмы развития и инициации ОС и НС при патологии легких. Охарактеризованы системы антиоксидантной защиты респираторного тракта. Представлены результаты исследования маркеров НС и ОС при различных заболеваниях респираторного тракта. Показано, что НС и ОС являются многоуровневыми сложнорегулируемыми процессами, существующими и развивающимися в нераздельной связи с рядом физиологических и патофизиологических процессов. Изучение механизмов НС и ОС способствует улучшению качества диагностики и побуждает к разработке новых терапевтических подходов и агентов, воздействующих на отдельные звенья патогенеза.

1. Ricciardolo F.L.M., Caramori G., Ito K. et al. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2005; 116 (5): 1028–1035. DOI: 10.1016/j.jaci.2005.06.034.

2. Соодаева С.К. Свободнорадикальные механизмы повреждения при болезнях органов дыхания. Пульмонология. 2012; (1): 5–10.

3. Sugiura H., Ichinose M. Nitrative stress in inflammatory lung diseases. Nitric Oxide. 2011; 25 (2): 138–144. DOI: 10.1016/j.niox.2011.03.079.

4. Dozor A.J. The role of oxidative stress in the pathogenesis and treatment of asthma. Ann. New York Academy of Sciences. 2010; 1203: 133–137. DOI: 10.1111/j.17496632.2010.05562.x.

5. Kirkham P.A., Barnes P.J. Oxidative stress in COPD. Chest. 2013; 144 (1): 266–273. DOI: 10.1378/chest.12-2664.

6. Antus B., Kardos Z. Oxidative stress in COPD: molecular background and clinical monitoring. Curr. Med. Chemistry. 2015; 22 (5): 627–650.

7. Соодаева С.К., Климанов И.А. Нарушения окислительного метаболизма при заболеваниях респираторного тракта и современные подходы к антиоксидантной терапии. Практическая пульмонология. 2009; (1): 34–38.

8. Соодаева С.К., Никитина Л.Ю., Климанов И.А. Механизмы развития оксидативного стресса под воздействием аэрополлютантов окружающей среды: потенциал средств антиоксидантной защиты. Пульмонология. 2015; 25 (6): 736–742. DOI: 10.18093/0869-0189-201525-6-736-742.

9. Berend N. Contribution of air pollution to COPD and small airway dysfunction. Respirology. 2016; 21 (2): 237–244. DOI: 10.1111/resp.12644.

10. BiaBas A.J., Sitarek P.B., Mibkowska-Dymanowska J. et al. The role of mitochondria and oxidative/antioxidative imbalance in pathobiology of chronic obstructive pulmonary disease. Oxid. Med. Cell. Long. 2016; 2016: 1–15. DOI: 10.1155/2016/7808576.

11. Владимиров Ю.А. Физико-химические основы патологии клетки: Курс лекций. М.; 2001.

12. Thomasi A., Ozden T., Sculachev V. Free radicals, nitric oxide, and inflammation: molecular, biochemical, and clinical aspects. In: NATO: Life and behavioural sciences. 344. Amsterdam: IOS Press; 2003: 71–88.

13. Соодаева С.К., Климанов И.А., Никитина Л.Ю. Особенности цикла оксида азота при респираторных заболеваниях. Пульмонология. 2016; 26 (6): 753–759. DOI: 10.18093/0869-0189-2016-26-6-753-759.

14. Ricciardolo F.L.M., Sterk P.J., Gaston B., Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol. Rev. 2004; 84 (3): 731–765. DOI: 10.1152/physrev.00034.2003.

15. Ricciardolo F.L. Multiple roles of nitric oxide in the airways. Thorax. 2003; 58 (2): 175–182.

16. Климанов И.А., Соодаева С.К. Механизмы формирования конденсата выдыхаемого воздуха и маркеры оксидативного стресса при патологиях респираторного тракта. Пульмонология. 2009; (2): 113–119.

17. Hanazawa T., Kharitonov S., Barnes P.J. Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am. J. Respir. Crit. Care Med. 2000; 162 (4): 1273–1276. DOI: 10.1164/ajrccm.162.4.9912064.

18. Corradi M., Montuschi P., Donnelly L.E. et al. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am. J. Respir. Crit. Care Med. 2001; 163 (4): 854–858. DOI: 10.1164/ajrccm.163.4.2001108.

19. Malerba M., Radaeli A., Olivini A. et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed. Res. Int. 2014; 2014: 271918. DOI: 10.1155/2014/271918.

20. Formanek W., Inci D., Lauener R.P. et al. Elevated nitrite in breath condensates of children with respiratory disease. Eur. Respir. J. 2002; 19 (3): 487–491.

21. Ho L.P., Innes J.A., Greening A.P. Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide. Thorax. 1998; 53 (8): 680–684.

22. Kharitonov S.A., Barnes P.J. Exhaled markers of inflammation. Curr. Opin. Allergy Clin. Immunol. 2001; 1 (3): 217–224.

23. McCafferty J.B., Bradshaw T.A., Tate S. et al. Effects of breathing pattern and inspired air conditions on breath condensate volume, pH, nitrite, and protein concentration. Thorax. 2004; 59: 694–698. DOI: 10.1136/thx.2003.016949.

24. Климанов И.А., Соодаева С.К., Лисица А.В. и др. Стандартизация преаналитического этапа исследования конденсата выдыхаемого воздуха. Пульмонология. 2006; (2): 53–55.

25. Millar T., Kanczler J., Bodamyali T. et al. Nitric Oxide. Its generation, reactions and role in physiology. In: NATO Conference Proceedings. 2001; 10–11.

26. Latzin P., Griese M. Exhaled hydrogen peroxide, nitrite and nitric oxide in healthy children: decrease of hydrogen peroxide by atmospheric nitric oxide. Eur. J. Med. Res. 2002; 7 (8): 353–358.

27. Emelyanov A., Fedoseev G., Abulimity A. et al. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest. 2001; 120 (4): 1136–1139.

28. Horvath I., Donnely L., Kiss A., Kharitonov S. Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am. J. Respir. Crit. Care Med. 1998; 158 (4): 1042–1046. DOI: 10.1164/ajrccm.158.4.9710091.

29. Ferreira I.M., Mehdi S. Hazari R.I. et al. Exhaled Nitric Oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164 (6): 1012–1101. DOI: 10.1164/ajrccm.164.6.2012139.

30. Dekhuijzen P.N., Aben K.K., Dekker I. et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 154 (3, Pt 1): 813–816.

31. van Beurden W.J., Dekhuijzen P.N., Harff G.A. et al. Variability of exhaled hydrogen peroxide in stable COPD patients and matched healthy controls. Respiration. 2002; 69 (3): 211–216.

32. Loukides S., Horvath I., Wodehouse T. et al. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am. J. Respir. Crit. Care Med. 1998; 158 (3): 991–914. DOI: 10.1164/ajrccm.158.3.9710031.

33. Majewska E., Kasielski M., Luczynski R. et al. Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respir. Med. 2004; 98 (7): 669–976.

34. Szkudlarek U., Maria L., Kasielski M. et al. Exhaled hydrogen peroxide correlates with the release of reactive oxygen species by blood phagocytes in healthy subjects. Respir. Med. 2003; 97 (6): 718–725.

35. Antczak A., Nowak D., Bialasiewicz P. et al. Hydrogen peroxide in expired air condensate correlates positively with early steps of peripheral neutrophil activation in asthmatic patients. Arch. Immunol. Ther. Exp. (Warsz.). 1999; 47 (2): 119–126.

36. Ho L.P., Faccenda J., Innes J.A. et al. Expired hydrogen peroxide in breath condensate of cystic fibrosis patients. Eur. Respir. J. 1999; 13 (1): 103–106.

37. Новоселов В.И. Роль пероксиредоксинов при окислительном стрессе в органах дыхания. Пульмонология. 2012; (1): 83–87.

38. Варламова Е.Г., Гольтяев М.В., Новоселов С.В. и др. Характеристика некоторых представителей суперсемейства тиоловых оксидоредуктаз. Молекулярная биология. 2013; 47 (4): 568–582.

39. Fridovich I. Superoxide radical and superoxide dismutases. Ann. Rev. Biochem. 1995; 64: 97–112. DOI: 10.1146/ annurev.bi.64.070195.000525.

40. Tainer J.A., Getzoff E.D., Richardson J.S. et al. Structure and mechanism of copper, zinc superoxide dismutase. Nature. 1983; 306 (5940): 284–287.

41. Hart P.J., Balbirnie M.M., Ogihara N.L. et al. A structurebased mechanism for copper-zinc superoxide dismutase. Biochemistry. 1999; 38 (7): 2167–2178. DOI: 10.1021/bi982284u.

42. Borgstahl G.E., Parge H.E., Hickey M.J. et al. The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell. 1992; 71 (1): 107–118. DOI: 10.1016/00928674(92)90270-M.

43. Gardner P.R., Raineri I., Epstein L.B. et al. Superoxide radical and iron modulate aconitase activity in mammalian cells. J. Biol. Chem. 1995; 270 (22): 13399–13405.

44. Chelikani P., Fita I., Loewen P.C. Diversity of structures and properties among catalases. Cell. Mol. Life Sci. 2004; 61 (2): 192–208. DOI: 10.1007/s00018-003-3206-5.

45. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000; 267 (7): 6102–6109.

46. Deponte M., Urig S., Arscott L.D. et al. Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase. J. Biol. Chem. 2005; 280: 20628–20637. DOI: 10.1074/jbc.M412519200.

47. Padayatty S.J., Katz A., Wang Y. et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J. Am. Coll. Nutr. 2003; 22 (1): 18–35.

48. Shigeoka S., Ishikawa T., Tamoi M. et al. Regulation and function of ascorbate peroxidase isoenzymes. J. Exp. Bot. 2002; 53 (372): 1305–1319.

49. Herrera E., Barbas C. Vitamin E: Action, metabolism and perspectives. J. Physiol. Biochem. 2001; 57 (1): 43–56.

50. Traber M.G., Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic. Biol. Med. 2007; 43 (1): 4–15. DOI: 10.1016/j.freeradbiomed.2007.03.024.

51. Kelly G.S. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 1998; 3 (2): 114–127.

52. Millea P.J. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician. 2009; 80 (3): 265–269.

53. Boesgaard S., Nielsen-Kudsk J.E., Laursen J.B. et al. Thiols and nitrates: reevaluation of the thiol depletion theory of nitrate tolerance. Am. J. Cardiol. 1998; 81: 21A–29A.

54. Zafarullah M., Li W.Q., Sylvester J., Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003; 60 (1): 6–20.

55. Amini A., Masoumi-Moghaddam S., Ehteda A., Morris D.L. Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J. Exp. Clin. Cancer. Res. 2014; 33 (1): 92. DOI: 10.1186/s13046-014-0092-7.

56. Gurbuz A.K., Ozel A.M., Ozturk R. et al. Effect of N-acetyl cysteine on Helicobacter pylori. South. Med. J. 2005; 98 (Suppl. 11): 1095–1097. DOI: 10.1097/01.smj.0000182486.39913.da.

57. Feldman L., Efrati S., Eviatar E. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007; 72 (3): 359–363. DOI: 10.1038/sj.ki.5002295.

58. Zhou J., Wang M., Sun Y. et al. Nitrate Increased Cucumber Tolerance to Fusarium Wilt by Regulating Fungal Toxin production and distribution. Toxins (Basel.). 2017; 9 (3): pii: E100. DOI: 10.3390/toxins9030100.

59. Tse H.N., Tseng C.Z.S. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 825–836. DOI: 10.2147/COPD.S51057.

60. Santus P., Corsico A., Solidoro P. et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD. 2014; 11 (6): 705–717. DOI: 10.3109/15412555.2014.898040.

61. Stav D., Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009; 136 (2): 381–386. DOI: 10.1378/chest.09-0421.

62. Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16 (2): 253–262.